Daniel L Hall1,2, Christina M Luberto1, Lisa L Philpotts3, Rhayun Song4, Elyse R Park1,5,6, Gloria Y Yeh2. 1. Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 2. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 3. Treadwell Library, Massachusetts General Hospital, Boston, MA, USA. 4. College of Nursing, Chungnam National University, South Korea. 5. Massachusetts General Hospital Cancer Center, Boston, MA, USA. 6. Mongan Institute Health Policy Center, Massachusetts General Hospital, Boston, MA, USA.
Abstract
OBJECTIVE: Fear of cancer recurrence (FCR) is a common existential concern and source of distress among adults with a cancer history. Multiple randomized controlled trials (RCTs) have examined mind-body approaches to mitigating FCR. We summarized characteristics of these trials and calculated their pooled effects on decreasing FCR. METHODS: Six electronic databases were systematically searched from inception to May 2017, using a strategy that included multiple terms for RCTs, cancer, mind-body medicine, and FCR. Data extraction and reporting followed Cochrane and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Pooled effect sizes on self-report measures of FCR were computed by using random-effects models. RESULTS: Nineteen RCTs (pooled N = 2806) were included. Most studies (53%) were published since 2015 and targeted a single cancer type (84%; mostly breast). Intervention sessions (median = 6, mode = 4) tended to last 120 minutes and occur across 1.5 months. Delivery was predominantly in-person (63%) to either groups (42%) or individuals (42%). Most interventions incorporated multiple mind-body components (53%), commonly cognitive-behavioral skills (58%), or meditative practices (53%). Small-to-medium pooled effect sizes were observed postintervention (Hedges' g = -0.36, 95% CI = -0.49, -0.23, P < .001) and at follow-up assessments (median = 8 months, P < .001). Potential modifiers (control group design, group/individual delivery, use of cognitive-behavioral or mindfulness skills, number of mind-body components, cancer treatment status, and number of sessions) did not reach statistical significance. CONCLUSIONS: Mind-body interventions are efficacious for reducing FCR, with small-to-medium effect sizes that persist after intervention delivery ends. Recommendations include testing effects among survivors of various cancers and exploring the optimal integration of mind-body practices for managing fundamental uncertainties and fears during cancer survivorship.
OBJECTIVE: Fear of cancer recurrence (FCR) is a common existential concern and source of distress among adults with a cancer history. Multiple randomized controlled trials (RCTs) have examined mind-body approaches to mitigating FCR. We summarized characteristics of these trials and calculated their pooled effects on decreasing FCR. METHODS: Six electronic databases were systematically searched from inception to May 2017, using a strategy that included multiple terms for RCTs, cancer, mind-body medicine, and FCR. Data extraction and reporting followed Cochrane and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Pooled effect sizes on self-report measures of FCR were computed by using random-effects models. RESULTS: Nineteen RCTs (pooled N = 2806) were included. Most studies (53%) were published since 2015 and targeted a single cancer type (84%; mostly breast). Intervention sessions (median = 6, mode = 4) tended to last 120 minutes and occur across 1.5 months. Delivery was predominantly in-person (63%) to either groups (42%) or individuals (42%). Most interventions incorporated multiple mind-body components (53%), commonly cognitive-behavioral skills (58%), or meditative practices (53%). Small-to-medium pooled effect sizes were observed postintervention (Hedges' g = -0.36, 95% CI = -0.49, -0.23, P < .001) and at follow-up assessments (median = 8 months, P < .001). Potential modifiers (control group design, group/individual delivery, use of cognitive-behavioral or mindfulness skills, number of mind-body components, cancer treatment status, and number of sessions) did not reach statistical significance. CONCLUSIONS: Mind-body interventions are efficacious for reducing FCR, with small-to-medium effect sizes that persist after intervention delivery ends. Recommendations include testing effects among survivors of various cancers and exploring the optimal integration of mind-body practices for managing fundamental uncertainties and fears during cancer survivorship.
Authors: Cecile A Lengacher; Richard R Reich; Carly L Paterson; Sophia Ramesar; Jong Y Park; Carissa Alinat; Versie Johnson-Mallard; Manolete Moscoso; Pinky Budhrani-Shani; Branko Miladinovic; Paul B Jacobsen; Charles E Cox; Matthew Goodman; Kevin E Kip Journal: J Clin Oncol Date: 2016-05-31 Impact factor: 44.544
Authors: Mbathio Dieng; Phyllis N Butow; Daniel S J Costa; Rachael L Morton; Scott W Menzies; Shab Mireskandari; Stephanie Tesson; Graham J Mann; Anne E Cust; Nadine A Kasparian Journal: J Clin Oncol Date: 2016-10-28 Impact factor: 44.544
Authors: Daniel L Hall; Inga T Lennes; William F Pirl; Emily R Friedman; Elyse R Park Journal: Support Care Cancer Date: 2016-12-13 Impact factor: 3.603
Authors: Michael H Antoni; Laura C Bouchard; Jamie M Jacobs; Suzanne C Lechner; Devika R Jutagir; Lisa M Gudenkauf; Charles S Carver; Susan Lutgendorf; Steven W Cole; Marc Lippman; Bonnie B Blomberg Journal: Psychoneuroendocrinology Date: 2016-09-24 Impact factor: 4.905
Authors: Paul C Nathan; Mark L Greenberg; Kirsten K Ness; Melissa M Hudson; Ann C Mertens; Martin C Mahoney; James G Gurney; Sarah S Donaldson; Wendy M Leisenring; Leslie L Robison; Kevin C Oeffinger Journal: J Clin Oncol Date: 2008-09-20 Impact factor: 50.717
Authors: Lauren E Latella; Madeline Rogers; Howard Leventhal; Patricia A Parker; Steven Horwitz; Matthew J Matasar; Carma L Bylund; David W Kissane; Kara Franco; Smita C Banerjee Journal: J Psychosoc Oncol Date: 2019-10-16
Authors: Shelley A Johns; Patrick V Stutz; Tasneem L Talib; Andrea A Cohee; Kathleen A Beck-Coon; Linda F Brown; Laura R Wilhelm; Patrick O Monahan; Michelle L LaPradd; Victoria L Champion; Kathy D Miller; R Brian Giesler Journal: Cancer Date: 2019-09-20 Impact factor: 6.860
Authors: Daniel L Hall; Rachel B Jimenez; Giselle K Perez; Julia Rabin; Katharine Quain; Gloria Y Yeh; Elyse R Park; Jeffrey M Peppercorn Journal: J Oncol Pract Date: 2019-07-12 Impact factor: 3.840
Authors: Kamila Osypiuk; Karen Kilgore; Jennifer Ligibel; Gloria Vergara-Diaz; Paolo Bonato; Peter M Wayne Journal: J Altern Complement Med Date: 2020-09 Impact factor: 2.579
Authors: Kelly Chinh; Catherine E Mosher; Linda F Brown; Kathleen A Beck-Coon; Kurt Kroenke; Shelley A Johns Journal: Mindfulness (N Y) Date: 2020-01-14